Correspondence 0001437749-24-015386 from AVENUE THERAPEUTICS, INC. (ATXI) (CIK 0001644963) (ATXI)
AVENUE THERAPEUTICS, INC. (ATXI) (CIK 0001644963)
Date: May 8, 2024 · CIK: 0001644963 · Accession: 0001437749-24-015386
AI Filing Summary & Sentiment
File numbers found in text: 333-279125
Letter
atxi20240508_corresp.htm
Correspondence.
Avenue Therapeutics, Inc.
1111 Kane Concourse, Suite 301
Bay Harbor Islands, Florida 33154
VIA EDGAR
May 8, 2024
Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attn: Chris Edwards
Re: Avenue Therapeutics, Inc.
Registration Statement on Form S-3 (Reg. No. 333-279125)
Request for Acceleration of Effective Date
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Avenue Therapeutics, Inc. (the “Company”) hereby requests that the Securities and Exchange Commission (the “Commission”) accelerate the effective date of the above-referenced Registration Statement on Form S-3 (the “Registration Statement”) so that the Registration Statement will be declared effective as of 4:00 p.m. Eastern time, on May 10, 2024, or as soon as practicable thereafter. The Company hereby authorizes Rakesh Gopalan or David S. Wolpa, both of whom are attorneys at the Company’s outside legal counsel, Troutman Pepper Hamilton Sanders LLP, to orally modify or withdraw this request for acceleration.
Once the Registration Statement has been declared effective, please orally confirm that event with Mr. Gopalan at (704) 916-2374 or Mr. Wolpa at (704) 916-2375.
Thank you for your assistance in this matter.
Very truly yours,
Avenue Therapeutics, Inc.
Show Raw Text
CORRESP 1 filename1.htm atxi20240508_corresp.htm Correspondence. Avenue Therapeutics, Inc. 1111 Kane Concourse, Suite 301 Bay Harbor Islands, Florida 33154 VIA EDGAR May 8, 2024 Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Chris Edwards Re: Avenue Therapeutics, Inc. Registration Statement on Form S-3 (Reg. No. 333-279125) Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Avenue Therapeutics, Inc. (the “Company”) hereby requests that the Securities and Exchange Commission (the “Commission”) accelerate the effective date of the above-referenced Registration Statement on Form S-3 (the “Registration Statement”) so that the Registration Statement will be declared effective as of 4:00 p.m. Eastern time, on May 10, 2024, or as soon as practicable thereafter. The Company hereby authorizes Rakesh Gopalan or David S. Wolpa, both of whom are attorneys at the Company’s outside legal counsel, Troutman Pepper Hamilton Sanders LLP, to orally modify or withdraw this request for acceleration. Once the Registration Statement has been declared effective, please orally confirm that event with Mr. Gopalan at (704) 916-2374 or Mr. Wolpa at (704) 916-2375. Thank you for your assistance in this matter. Very truly yours, Avenue Therapeutics, Inc. /s/ Alexandra MacLean Name: Alexandra MacLean Title: Chief Executive Officer cc (via email): Rakesh Gopalan and David Wolpa, Troutman Pepper Hamilton Sanders LLP